526P - A retrospective study on the protective effect of nonsteroidal anti-inflammatory drugs on panitumumab-related skin symptoms

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer Agents
Complications/Toxicities of Treatment
Supportive Measures
Presenter Hiroshi Ishikawa
Citation Annals of Oncology (2016) 27 (suppl_9): ix170-ix176. 10.1093/annonc/mdw599
Authors H. Ishikawa1, H. Masujima2, R. Tanaka1, T. Kamoshida1, M. Shino1, K. Yamazaki3
  • 1Pharmacy, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 2Pharmacy, Shizuoka Cancer Center, Shizuoka/JP
  • 3Gastrointestinal Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP



An acneiform eruption, the most frequently observed adverse event due to anti-epidermal growth factor receptor (EGFR) antibodies, is reported due to local inhibition of EGFR. The utility of nonsteroidal anti-inflammatory drugs (NSAIDs) for the acneiform eruption due to erlotinib, an EGFR tyrosine kinase inhibitor, has been reported; thus, a protective effect of NSAIDs on an acneiform eruption has been expected. The objective of this study is to examine the protective effect of NSAIDs on the acneiform eruption due to panitumumab (Pmab).


This study comprised 104 patients with KRAS wild-type unresectable advanced/recurrent colorectal cancer who treated with either Pmab and concomitant NSAIDs (concomitant group) or Pmab alone (non-concomitant group) from April 2010 to March 2016. The protective effects of NSAIDs on Pmab-related skin symptoms were retrospectively and comparatively examined regarding age, sex, ECOG performance status, treatment line, treatment regimen, and incidence rate of acneiform eruption. The period of this study was limited to the first 6 cycles from initiation of Pmab treatment, because the acneiform eruption due to Pmab were frequently observed during this period. Patients treated with protective topical or oral steroids after the time that Pmab treatment was started were excluded from this study.


Of the 104 patients, 37 were in the concomitant group and 67 in the non-concomitant group. The incidence of acneiform eruption in the concomitant group and non-concomitant group were 74.3% and 88.7% (P value = 0.0498), respectively; the numbers of patients with grade 0, 1, 2, 3, and 4 acneiform eruption in the concomitant group were 10, 20, 7, 0, and 0, and those who in the non-concomitant group were 7, 41, 18, 1, and 0 (P value = 0.0495), respectively. The significant differences in both incidence and severity of acneiform eruption were observed between the two groups.


The concomitant use of oral NSAIDs seemed to be useful for the prevention of acneiform eruption due to Pmab.

Clinical trial indentification

Legal entity responsible for the study

Shizuoka Cancer Center


Shizuoka Cancer Center


All authors have declared no conflicts of interest.